Wells Fargo Maintains Equal-Weight on Fate Therapeutics, Lowers Price Target to $3
Benzinga Newsdesk 13 hours ago
Analyst RatingsNewsPrice Target
Wells Fargo analyst Yanan Zhu maintains Fate Therapeutics (NASDAQ:FATE) with a Equal-Weight and lowers the price target from $3.5 to $3.
Wells Fargo analyst Yanan Zhu maintains Fate Therapeutics (NASDAQ:FATE) with a Equal-Weight and lowers the price target from $3.5 to $3.